Table 1. Open in new tab Breast cancer...

PRS investigated and outcome	BRCA1 carriers	BRCA2 carriers
PRS_BC
PRS_BC association with breast cancer risk
Continuous^b	380	33	1.40 (1.06 to 1.85)	.02	933	244	1.32 (1.15 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.05 to 1.84)	.02	933	244	1.33 (1.15 to 1.52)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.44 (1.07 to 1.95)	.02	933	244	1.36 (1.18 to 1.57)	<.001
PRS_BC association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.63 to 1.67)^g	.92	—	11	1.33 (0.74 to 2.36)	.34
Grade 2	—	6	—	68	1.29 (1.04 to 1.60)	.02
Grade 3	—	12	1.56 (1.03 to 2.37)	.04	—	98	1.23 (1.00 to 1.50)	.05
Grade unknown	—	14	1.47 (0.93 to 2.32)	.10	—	67	1.51 (1.18 to 1.93)	.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	6.30 (0.88 to 44.87)	.07	79	98	0.95 (0.71 to 1.27)	.73
PRS_ER-
PRS_ER- association with breast cancer risk
Continuous^b	380	33	1.12 (0.79 to 1.59)	.52	933	244	1.23 (1.07 to 1.41)	.004
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.12 (0.79 to 1.59)	.53	933	244	1.23 (1.07 to 1.42)	.004
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.14 (0.80 to 1.63)	.48	933	244	1.25 (1.09 to 1.45)	.002
PRS_ER- association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
ER negative	—	2	0.38 (0.06 to 2.29)	.29	—	7	0.51 (0.27 to 0.98)	.04
ER positive	—	21	1.47 (0.97 to 2.24)	.07	—	178	1.26 (1.08 to 1.47)	.004
ER status unknown	—	10	0.78 (0.46 to 1.30)	.34	—	59	1.24 (0.94 to 1.64)	.13
PRS_ER+
PRS_ER+ association with breast cancer risk
Continuous^b	380	33	1.40 (1.07 to 1.83)	.01	933	244	1.33 (1.16 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.06 to 1.82)	.02	933	244	1.33 (1.16 to 1.53)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.46 (1.09 to 1.94)	.01	933	244	1.36 (1.18 to 1.57)	<.001
PRS_ER+ association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
ER negative	—	2	0.35 (0.03 to 3.59)	.37	—	7	0.68 (0.38 to 1.22)	.20
ER positive	—	21	1.79 (1.30 to 2.48)	<.001	—	178	1.30 (1.11 to 1.52)	<.001
ER status unknown	—	10	1.00 (0.68 to 1.47)	1.00	—	59	1.52 (1.18 to 1.94)	.001
PRS_ER+ association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.65 to 1.65)^g	.89	—	11	1.31 (0.76 to 2.27)	.34
Grade 2	—	6	—	68	1.29 (1.05 to 1.59)	.02
Grade 3	—	12	1.51 (1.04 to 2.19)	.03	—	98	1.23 (1.01 to 1.51)	.04
Grade unknown	—	14	1.51 (0.96 to 2.38)	.07	—	67	1.51 (1.19 to 1.92)	<.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	5.41 (0.79 to 37.20)	.09	79	98	0.95 (0.71 to 1.28)	.75

PRS investigated and outcome

BRCA1 carriers

BRCA2 carriers

No. of controls

No. of cases

OR (95% CI)

P^a

No. of controls

No. of cases

OR (95% CI)

P^a

PRS_BC

PRS_BC association with breast cancer risk

Continuous^b

380

1.40 (1.06 to 1.85)

.02

933

244

1.32 (1.15 to 1.52)

<.001

Continuous: adjusted for male relative breast cancer FH^c

380

1.39 (1.05 to 1.84)

.02

933

244

1.33 (1.15 to 1.52)

<.001

Continuous: adjusted for female relative breast cancer FH^c

380

1.44 (1.07 to 1.95)

.02

933

244

1.36 (1.18 to 1.57)

<.001

PRS_BC association with grade-specific breast cancer risk^d

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

Grade 1

—

1.03 (0.63 to 1.67)^g

.92

—

1.33 (0.74 to 2.36)

.34

Grade 2

—

1.29 (1.04 to 1.60)

.02

Grade 3

—

1.56 (1.03 to 2.37)

.04

—

1.23 (1.00 to 1.50)

.05

Grade unknown

—

1.47 (0.93 to 2.32)

.10

—

1.51 (1.18 to 1.93)

.001

Case-only: grade 1 + 2 vs grade 3^e

6.30 (0.88 to 44.87)

.07

0.95 (0.71 to 1.27)

.73

PRS_ER-

PRS_ER- association with breast cancer risk

Continuous^b

380

1.12 (0.79 to 1.59)

.52

933

244

1.23 (1.07 to 1.41)

.004

Continuous: adjusted for male relative breast cancer FH^c

380

1.12 (0.79 to 1.59)

.53

933

244

1.23 (1.07 to 1.42)

.004

Continuous: adjusted for female relative breast cancer FH^c

380

1.14 (0.80 to 1.63)

.48

933

244

1.25 (1.09 to 1.45)

.002

PRS_ER- association with ER-specific breast cancer risk^f

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

ER negative

—

0.38 (0.06 to 2.29)

.29

—

0.51 (0.27 to 0.98)

.04

ER positive

—

1.47 (0.97 to 2.24)

.07

—

178

1.26 (1.08 to 1.47)

.004

ER status unknown

—

0.78 (0.46 to 1.30)

.34

—

1.24 (0.94 to 1.64)

.13

PRS_ER+

PRS_ER+ association with breast cancer risk

Continuous^b

380

1.40 (1.07 to 1.83)

.01

933

244

1.33 (1.16 to 1.52)

<.001

Continuous: adjusted for male relative breast cancer FH^c

380

1.39 (1.06 to 1.82)

.02

933

244

1.33 (1.16 to 1.53)

<.001

Continuous: adjusted for female relative breast cancer FH^c

380

1.46 (1.09 to 1.94)

.01

933

244

1.36 (1.18 to 1.57)

<.001

PRS_ER+ association with ER-specific breast cancer risk^f

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

ER negative

—

0.35 (0.03 to 3.59)

.37

—

0.68 (0.38 to 1.22)

.20

ER positive

—

1.79 (1.30 to 2.48)

<.001

—

178

1.30 (1.11 to 1.52)

<.001

ER status unknown

—

1.00 (0.68 to 1.47)

1.00

—

1.52 (1.18 to 1.94)

.001

PRS_ER+ association with grade-specific breast cancer risk^d

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

Grade 1

—

1.03 (0.65 to 1.65)^g

.89

—

1.31 (0.76 to 2.27)

.34

Grade 2

—

1.29 (1.05 to 1.59)

.02

Grade 3

—

1.51 (1.04 to 2.19)

.03

—

1.23 (1.01 to 1.51)

.04

Grade unknown

—

1.51 (0.96 to 2.38)

.07

—

1.51 (1.19 to 1.92)

<.001

Case-only: grade 1 + 2 vs grade 3^e

5.41 (0.79 to 37.20)

.09

0.95 (0.71 to 1.28)

.75

PRS investigated and outcome	BRCA1 carriers	BRCA2 carriers
PRS_BC
PRS_BC association with breast cancer risk
Continuous^b	380	33	1.40 (1.06 to 1.85)	.02	933	244	1.32 (1.15 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.05 to 1.84)	.02	933	244	1.33 (1.15 to 1.52)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.44 (1.07 to 1.95)	.02	933	244	1.36 (1.18 to 1.57)	<.001
PRS_BC association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.63 to 1.67)^g	.92	—	11	1.33 (0.74 to 2.36)	.34
Grade 2	—	6	—	68	1.29 (1.04 to 1.60)	.02
Grade 3	—	12	1.56 (1.03 to 2.37)	.04	—	98	1.23 (1.00 to 1.50)	.05
Grade unknown	—	14	1.47 (0.93 to 2.32)	.10	—	67	1.51 (1.18 to 1.93)	.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	6.30 (0.88 to 44.87)	.07	79	98	0.95 (0.71 to 1.27)	.73
PRS_ER-
PRS_ER- association with breast cancer risk
Continuous^b	380	33	1.12 (0.79 to 1.59)	.52	933	244	1.23 (1.07 to 1.41)	.004
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.12 (0.79 to 1.59)	.53	933	244	1.23 (1.07 to 1.42)	.004
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.14 (0.80 to 1.63)	.48	933	244	1.25 (1.09 to 1.45)	.002
PRS_ER- association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
ER negative	—	2	0.38 (0.06 to 2.29)	.29	—	7	0.51 (0.27 to 0.98)	.04
ER positive	—	21	1.47 (0.97 to 2.24)	.07	—	178	1.26 (1.08 to 1.47)	.004
ER status unknown	—	10	0.78 (0.46 to 1.30)	.34	—	59	1.24 (0.94 to 1.64)	.13
PRS_ER+
PRS_ER+ association with breast cancer risk
Continuous^b	380	33	1.40 (1.07 to 1.83)	.01	933	244	1.33 (1.16 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.06 to 1.82)	.02	933	244	1.33 (1.16 to 1.53)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.46 (1.09 to 1.94)	.01	933	244	1.36 (1.18 to 1.57)	<.001
PRS_ER+ association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
ER negative	—	2	0.35 (0.03 to 3.59)	.37	—	7	0.68 (0.38 to 1.22)	.20
ER positive	—	21	1.79 (1.30 to 2.48)	<.001	—	178	1.30 (1.11 to 1.52)	<.001
ER status unknown	—	10	1.00 (0.68 to 1.47)	1.00	—	59	1.52 (1.18 to 1.94)	.001
PRS_ER+ association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)	933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.65 to 1.65)^g	.89	—	11	1.31 (0.76 to 2.27)	.34
Grade 2	—	6	—	68	1.29 (1.05 to 1.59)	.02
Grade 3	—	12	1.51 (1.04 to 2.19)	.03	—	98	1.23 (1.01 to 1.51)	.04
Grade unknown	—	14	1.51 (0.96 to 2.38)	.07	—	67	1.51 (1.19 to 1.92)	<.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	5.41 (0.79 to 37.20)	.09	79	98	0.95 (0.71 to 1.28)	.75

PRS investigated and outcome

BRCA1 carriers

BRCA2 carriers

No. of controls

No. of cases

OR (95% CI)

P^a

No. of controls

No. of cases

OR (95% CI)

P^a

PRS_BC

PRS_BC association with breast cancer risk

Continuous^b

380

1.40 (1.06 to 1.85)

.02

933

244

1.32 (1.15 to 1.52)

<.001

Continuous: adjusted for male relative breast cancer FH^c

380

1.39 (1.05 to 1.84)

.02

933

244

1.33 (1.15 to 1.52)

<.001

Continuous: adjusted for female relative breast cancer FH^c

380

1.44 (1.07 to 1.95)

.02

933

244

1.36 (1.18 to 1.57)

<.001

PRS_BC association with grade-specific breast cancer risk^d

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

Grade 1

—

1.03 (0.63 to 1.67)^g

.92

—

1.33 (0.74 to 2.36)

.34

Grade 2

—

1.29 (1.04 to 1.60)

.02

Grade 3

—

1.56 (1.03 to 2.37)

.04

—

1.23 (1.00 to 1.50)

.05

Grade unknown

—

1.47 (0.93 to 2.32)

.10

—

1.51 (1.18 to 1.93)

.001

Case-only: grade 1 + 2 vs grade 3^e

6.30 (0.88 to 44.87)

.07

0.95 (0.71 to 1.27)

.73

PRS_ER-

PRS_ER- association with breast cancer risk

Continuous^b

380

1.12 (0.79 to 1.59)

.52

933

244

1.23 (1.07 to 1.41)

.004

Continuous: adjusted for male relative breast cancer FH^c

380

1.12 (0.79 to 1.59)

.53

933

244

1.23 (1.07 to 1.42)

.004

Continuous: adjusted for female relative breast cancer FH^c

380

1.14 (0.80 to 1.63)

.48

933

244

1.25 (1.09 to 1.45)

.002

PRS_ER- association with ER-specific breast cancer risk^f

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

ER negative

—

0.38 (0.06 to 2.29)

.29

—

0.51 (0.27 to 0.98)

.04

ER positive

—

1.47 (0.97 to 2.24)

.07

—

178

1.26 (1.08 to 1.47)

.004

ER status unknown

—

0.78 (0.46 to 1.30)

.34

—

1.24 (0.94 to 1.64)

.13

PRS_ER+

PRS_ER+ association with breast cancer risk

Continuous^b

380

1.40 (1.07 to 1.83)

.01

933

244

1.33 (1.16 to 1.52)

<.001

Continuous: adjusted for male relative breast cancer FH^c

380

1.39 (1.06 to 1.82)

.02

933

244

1.33 (1.16 to 1.53)

<.001

Continuous: adjusted for female relative breast cancer FH^c

380

1.46 (1.09 to 1.94)

.01

933

244

1.36 (1.18 to 1.57)

<.001

PRS_ER+ association with ER-specific breast cancer risk^f

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

ER negative

—

0.35 (0.03 to 3.59)

.37

—

0.68 (0.38 to 1.22)

.20

ER positive

—

1.79 (1.30 to 2.48)

<.001

—

178

1.30 (1.11 to 1.52)

<.001

ER status unknown

—

1.00 (0.68 to 1.47)

1.00

—

1.52 (1.18 to 1.94)

.001

PRS_ER+ association with grade-specific breast cancer risk^d

Controls

380

—

1.00 (referent)

933

—

1.00 (referent)

Grade 1

—

1.03 (0.65 to 1.65)^g

.89

—

1.31 (0.76 to 2.27)

.34

Grade 2

—

1.29 (1.05 to 1.59)

.02

Grade 3

—

1.51 (1.04 to 2.19)

.03

—

1.23 (1.01 to 1.51)

.04

Grade unknown

—

1.51 (0.96 to 2.38)

.07

—

1.51 (1.19 to 1.92)

<.001

Case-only: grade 1 + 2 vs grade 3^e

5.41 (0.79 to 37.20)

.09

0.95 (0.71 to 1.28)

.75

Table 1.

Open in new tab

Breast cancer PRS associations with breast cancer risk for BRCA1 and BRCA2 carriers

PRS investigated and outcome	BRCA1 carriers				BRCA2 carriers
PRS investigated and outcome	No. of controls	No. of cases	OR (95% CI)	P^a	No. of controls	No. of cases	OR (95% CI)	P^a
PRS_BC
PRS_BC association with breast cancer risk
Continuous^b	380	33	1.40 (1.06 to 1.85)	.02	933	244	1.32 (1.15 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.05 to 1.84)	.02	933	244	1.33 (1.15 to 1.52)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.44 (1.07 to 1.95)	.02	933	244	1.36 (1.18 to 1.57)	<.001
PRS_BC association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.63 to 1.67)^g	.92	—	11	1.33 (0.74 to 2.36)	.34
Grade 2	—	6	1.03 (0.63 to 1.67)^g	.92	—	68	1.29 (1.04 to 1.60)	.02
Grade 3	—	12	1.56 (1.03 to 2.37)	.04	—	98	1.23 (1.00 to 1.50)	.05
Grade unknown	—	14	1.47 (0.93 to 2.32)	.10	—	67	1.51 (1.18 to 1.93)	.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	6.30 (0.88 to 44.87)	.07	79	98	0.95 (0.71 to 1.27)	.73
PRS_ER-
PRS_ER- association with breast cancer risk
Continuous^b	380	33	1.12 (0.79 to 1.59)	.52	933	244	1.23 (1.07 to 1.41)	.004
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.12 (0.79 to 1.59)	.53	933	244	1.23 (1.07 to 1.42)	.004
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.14 (0.80 to 1.63)	.48	933	244	1.25 (1.09 to 1.45)	.002
PRS_ER- association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
ER negative	—	2	0.38 (0.06 to 2.29)	.29	—	7	0.51 (0.27 to 0.98)	.04
ER positive	—	21	1.47 (0.97 to 2.24)	.07	—	178	1.26 (1.08 to 1.47)	.004
ER status unknown	—	10	0.78 (0.46 to 1.30)	.34	—	59	1.24 (0.94 to 1.64)	.13
PRS_ER+
PRS_ER+ association with breast cancer risk
Continuous^b	380	33	1.40 (1.07 to 1.83)	.01	933	244	1.33 (1.16 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.06 to 1.82)	.02	933	244	1.33 (1.16 to 1.53)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.46 (1.09 to 1.94)	.01	933	244	1.36 (1.18 to 1.57)	<.001
PRS_ER+ association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
ER negative	—	2	0.35 (0.03 to 3.59)	.37	—	7	0.68 (0.38 to 1.22)	.20
ER positive	—	21	1.79 (1.30 to 2.48)	<.001	—	178	1.30 (1.11 to 1.52)	<.001
ER status unknown	—	10	1.00 (0.68 to 1.47)	1.00	—	59	1.52 (1.18 to 1.94)	.001
PRS_ER+ association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.65 to 1.65)^g	.89	—	11	1.31 (0.76 to 2.27)	.34
Grade 2	—	6	1.03 (0.65 to 1.65)^g	.89	—	68	1.29 (1.05 to 1.59)	.02
Grade 3	—	12	1.51 (1.04 to 2.19)	.03	—	98	1.23 (1.01 to 1.51)	.04
Grade unknown	—	14	1.51 (0.96 to 2.38)	.07	—	67	1.51 (1.19 to 1.92)	<.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	5.41 (0.79 to 37.20)	.09	79	98	0.95 (0.71 to 1.28)	.75

PRS investigated and outcome	BRCA1 carriers				BRCA2 carriers
PRS investigated and outcome	No. of controls	No. of cases	OR (95% CI)	P^a	No. of controls	No. of cases	OR (95% CI)	P^a
PRS_BC
PRS_BC association with breast cancer risk
Continuous^b	380	33	1.40 (1.06 to 1.85)	.02	933	244	1.32 (1.15 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.05 to 1.84)	.02	933	244	1.33 (1.15 to 1.52)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.44 (1.07 to 1.95)	.02	933	244	1.36 (1.18 to 1.57)	<.001
PRS_BC association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.63 to 1.67)^g	.92	—	11	1.33 (0.74 to 2.36)	.34
Grade 2	—	6	1.03 (0.63 to 1.67)^g	.92	—	68	1.29 (1.04 to 1.60)	.02
Grade 3	—	12	1.56 (1.03 to 2.37)	.04	—	98	1.23 (1.00 to 1.50)	.05
Grade unknown	—	14	1.47 (0.93 to 2.32)	.10	—	67	1.51 (1.18 to 1.93)	.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	6.30 (0.88 to 44.87)	.07	79	98	0.95 (0.71 to 1.27)	.73
PRS_ER-
PRS_ER- association with breast cancer risk
Continuous^b	380	33	1.12 (0.79 to 1.59)	.52	933	244	1.23 (1.07 to 1.41)	.004
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.12 (0.79 to 1.59)	.53	933	244	1.23 (1.07 to 1.42)	.004
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.14 (0.80 to 1.63)	.48	933	244	1.25 (1.09 to 1.45)	.002
PRS_ER- association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
ER negative	—	2	0.38 (0.06 to 2.29)	.29	—	7	0.51 (0.27 to 0.98)	.04
ER positive	—	21	1.47 (0.97 to 2.24)	.07	—	178	1.26 (1.08 to 1.47)	.004
ER status unknown	—	10	0.78 (0.46 to 1.30)	.34	—	59	1.24 (0.94 to 1.64)	.13
PRS_ER+
PRS_ER+ association with breast cancer risk
Continuous^b	380	33	1.40 (1.07 to 1.83)	.01	933	244	1.33 (1.16 to 1.52)	<.001
Continuous: adjusted for male relative breast cancer FH^c	380	33	1.39 (1.06 to 1.82)	.02	933	244	1.33 (1.16 to 1.53)	<.001
Continuous: adjusted for female relative breast cancer FH^c	380	33	1.46 (1.09 to 1.94)	.01	933	244	1.36 (1.18 to 1.57)	<.001
PRS_ER+ association with ER-specific breast cancer risk^f
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
ER negative	—	2	0.35 (0.03 to 3.59)	.37	—	7	0.68 (0.38 to 1.22)	.20
ER positive	—	21	1.79 (1.30 to 2.48)	<.001	—	178	1.30 (1.11 to 1.52)	<.001
ER status unknown	—	10	1.00 (0.68 to 1.47)	1.00	—	59	1.52 (1.18 to 1.94)	.001
PRS_ER+ association with grade-specific breast cancer risk^d
Controls	380	—	1.00 (referent)		933	—	1.00 (referent)
Grade 1	—	1	1.03 (0.65 to 1.65)^g	.89	—	11	1.31 (0.76 to 2.27)	.34
Grade 2	—	6	1.03 (0.65 to 1.65)^g	.89	—	68	1.29 (1.05 to 1.59)	.02
Grade 3	—	12	1.51 (1.04 to 2.19)	.03	—	98	1.23 (1.01 to 1.51)	.04
Grade unknown	—	14	1.51 (0.96 to 2.38)	.07	—	67	1.51 (1.19 to 1.92)	<.001
Case-only: grade 1 + 2 vs grade 3^e	7	12	5.41 (0.79 to 37.20)	.09	79	98	0.95 (0.71 to 1.28)	.75

P value was calculated using a 2-sided Wald test. CI = confidence interval; ER = estrogen receptor; FH = family history; OR = odds ratio per PRS standard deviation, estimated from a multinomial logistic regression (unless otherwise stated); PRS = polygenic risk scores PRS_BC = overall breast cancer PRS; PRS_ER- = ER-negative breast cancer PRS; PRS_ER+ = ER-positive breast cancer PRS.

The continuous test shows the per PRS standard deviation associations, estimated from a multinomial logistic regression model assuming a continuous PRS.

Association estimates adjusted for family history of (male and female) breast cancer in first- and second-degree relatives. FH was coded as no family history, 1 or more relatives diagnosed with breast cancer, unknown FH or missing FH. Supplementary Table 8 (available online; male breast cancer FH adjusted) and Supplementary Table 9 (available online; female breast cancer FH adjusted) describe the breast cancer FH adjusted analyses in greater detail.

The breast cancer grade specific odds ratios were estimated by partitioning breast cancer status into multinomial outcomes for grade 1, grade 2, grade 3, or grade unknown.

The case-only breast cancer grade analysis was a logistic regression considering grade 1 and grade 2 breast cancers combined as controls and grade 3 breast cancers as cases.

The ER-specific breast cancer odds ratios were estimated by partitioning breast cancer status into distinct multinomial outcomes for ER negative, ER positive, or ER status unknown.

Grade 1 and grade 2 combined for BRCA1 carriers (to ensure adequate sample size to estimate associations).

This Feature Is Available To Subscribers Only